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Background
The study was aimed at evaluating the cost-effectiveness
of immunotherapy (IT) for children (Ch) with atopic
dermatitis (AD).
Methods
There were examined 94 Ch aged 3-18 years with AD
and duration of disease 1-15 years. Patients underwent
the standard general clinical and immunological and
allergy survey. The treatment consisted of 2 stages: tradi-
tional therapy (TT) for reducing disease complications,
and IT. Patients were divided in 3 groups: I group (n=30)
received stepped therapy with immune response-modu-
lating agent (IRMA) in course dose of 20mg; II group
(n=31) was treated with parenteral accelerated allergen-
specific immunotherapy (APAI); III group (n=33)
received combination of IT - CIT (IRMA+APAI) on the
fast track scheme. Pharmacoeconomic assessments were
performed using cost-effectiveness analysis.
Results
The cost of a pack of IRMA was $7.67. The cost of 1 year
APAI was $32.2. After 2 courses of IRMA the TT costs in
I group were $189.69±1.08, in II group– $69.14±0.93, and
in III group– $32.34. Three years of 2 consecutive courses
in I group resulted in mean treatment costs of $569.06; 3
consecutive courses in II group– in mean treatment costs
of $104.00, and $97.01 in III group for the same period. In
addition, CIT provided long-term remission, reduced
number of hospitalization, prevented AD progression,
improved skin condition of children with AD, thus
normalizing emotional balance. Furthermore there was
indirect costs minimization - 2/3 reduction of parents’ sick
leaves payments.
Conclusions
The clinico-economic analysis showed that despite the
complexity of APAI, CIT method improves the quality
of life of children with AD, provides pharmacotherapy
and medical services costs reduction, and it is more
cost-effective.
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